Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALKALINE lorlatinib trial in ALK-positive NSCLC after second-generation ALK inhibitor failure
NL-OMON55136Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Dec 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lorlatinib in non-small cell lung cancer (NSCLC), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoints: Progression-free survival rate at 12 months and Time from emergence of ALK resistance mutation to radiological progressive disease. Started Dec 2020; status: completed.
02
Drugs
lorlatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON55136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55136.